Cesari M, Bernabei R, Vellas B, Fielding R A, Rooks D, Azzolino D, Mariani J, Oliva A A, Bhasin S, Rolland Y
Prof. Matteo Cesari; Geriatric Unit, IRCCS Istituti Clinici Scientifici Maugeri; Via Camaldoli 64, 20138 Milano, Italy; Twitter: @macesari; E-mail:
J Frailty Aging. 2022;11(2):135-142. doi: 10.14283/jfa.2022.30.
Sarcopenia and frailty represent two burdensome conditions, contributing to a broad spectrum of adverse outcomes. The International Conference on Frailty and Sarcopenia Research (ICFSR) Task Force met virtually in September 2021 to discuss the challenges in the development of drugs for sarcopenia and frailty. Lifestyle interventions are the current mainstay of treatment options in the prevention and management of both conditions. However, pharmacological agents are needed for people who do not respond to lifestyle modifications, for those who are unable to adhere, or for whom such interventions are inaccessible/unfeasible. Preliminary results of ongoing trials were presented and discussed. Several pharmacological candidates are currently under clinical evaluation with promising early results, but none have been approved for either frailty or sarcopenia. The COVID-19 pandemic has reshaped how clinical trials are conducted, in particular by enhancing the usefulness of remote technologies and assessments/interventions.
肌肉减少症和衰弱是两种负担沉重的状况，会导致一系列不良后果。衰弱与肌肉减少症研究国际会议（ICFSR）特别工作组于2021年9月举行了线上会议，讨论肌肉减少症和衰弱症药物研发面临的挑战。生活方式干预是目前预防和管理这两种病症的主要治疗选择。然而，对于那些对生活方式改变无反应、无法坚持或无法进行此类干预的人来说，需要使用药物治疗。会上介绍并讨论了正在进行的试验的初步结果。目前有几种候选药物正在进行临床评估，早期结果很有前景，但尚无药物获批用于治疗衰弱或肌肉减少症。新冠疫情改变了临床试验的开展方式，特别是增强了远程技术以及评估/干预措施的实用性。
